Syntropharma development activities are focused on the repositioning/reformulation of existing approved drugs.
The adoption of this strategy has helped Syntropharma develop a number of transdermal products quickly and efficiently.
Syntropharma’s first technology led to the development of a new transdermal product that was recently approved for use by the Argentinean regulatory authorities (ANMAT). Other regulatory approvals are expected.
Historically the Company’s preferred method of reformulation has utilised transdermal technology (patches). This is because it is possible to improve many of the problems associated with oral dosing, such as bioavailability, side effects and poor compliance.
Syntropharma have demonstrated there are numerous other drug candidates that can be developed as patches and that are desirable to the pharmaceutical industry.